Cargando…

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study

SIMPLE SUMMARY: Herein, we retrospectively analyze in our single-center study real-life data of 357 myeloma and lymphoma patients mobilized with granulocyte colony-stimulating factor plus a fixed dose of Plerixafor when indicated or G-CSF alone. There were no significant differences in engraftment k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steiner, Normann, Göbel, Georg, Mauser, Leonie, Mühlnikel, Lena, Fischinger, Marie, Künz, Tina, Willenbacher, Wolfgang, Hetzenauer, Gabriele, Rudzki, Jakob, Nussbaumer, Walter, Mayer, Wolfgang, Gunsilius, Eberhard, Kircher, Brigitte, Wolf, Dominik, Nachbaur, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913576/ https://www.ncbi.nlm.nih.gov/pubmed/36765566 http://dx.doi.org/10.3390/cancers15030608

Ejemplares similares

Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience
por: Steiner, Normann, et al.
Publicado: (2021)

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)
por: Künz, Tina, et al.
Publicado: (2022)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
por: Steiner, Normann, et al.
Publicado: (2016)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?
por: Steiner, N., et al.
Publicado: (2019)

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia
por: Willenbacher, Ella, et al.
Publicado: (2019)

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
por: Steiner, Normann, et al.
Publicado: (2018)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia‐variant
por: Locher, Maurus, et al.
Publicado: (2020)

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
por: Pircher, Andreas, et al.
Publicado: (2016)

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury
por: Steiner, N., et al.
Publicado: (2020)

Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report
por: Al-Zoairy, R., et al.
Publicado: (2020)

Circumnavigating the challenges of COVID-19 in oncology
por: Fuereder, Thorsten, et al.
Publicado: (2020)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study
por: Antlanger, Marlies, et al.
Publicado: (2018)

Interesting news from the annual meeting of the American Society of Hematology 2020
por: Gunsilius, Eberhard
Publicado: (2021)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Creating the “new normal” post-Coronavirus world—web-communication replacing face-to-face interaction
por: Hilbe, Wolfgang, et al.
Publicado: (2020)

Risk factors for poorer health literacy in patients with liver cirrhosis
por: Kaps, Leonard, et al.
Publicado: (2021)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

National Insurance and the Poorer Hospitals
Publicado: (1914)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

A Plea for Sanatoria for the Poorer Consumptives
por: Weatherly, Lionel A.
Publicado: (1900)

High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
por: Schaffrath, Judith, et al.
Publicado: (2022)

Deprivation amplification revisited; or, is it always true that poorer places have poorer access to resources for healthy diets and physical activity?
por: Macintyre, Sally
Publicado: (2007)

Are Psychotic Experiences Related to Poorer Reflective Reasoning?
por: Mækelæ, Martin J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_afovl3gjotn0mbdpssfb5dk4hq